U.S. Biotech Stock News

In recent weeks, Lantheus Holdings has drawn increased attention after multiple research firms reiterated positive ratings on the company, with nearly 80% of covering analysts assigning it a Buy‑equivalent view despite ongoing pricing and competitive pressures on its Pylarify prostate cancer imaging franchise. What stands out is that this supportive analyst stance comes as Truist Securities highlights Lantheus’ strong financial health and margins that compare favorably with many peers, at a...

If you are wondering whether Copart's recent slide has turned it into a potential value opportunity, or if the market sees trouble ahead, this breakdown is for you. Copart is down about 0.1% over the last week, roughly 6.3% over the last month, and a steep 31.3% year to date, with the 1-year return sitting at around negative 36.8%. However, the 3- and 5-year returns are still positive at 28.1% and 26.4% respectively. These moves come as investors reassess the outlook for vehicle volumes,...

The Federal Reserve’s recent 25-basis-point interest rate cut, aimed at supporting economic growth through lower borrowing costs, has lifted sentiment toward consumer-facing companies like apparel and accessories maker VF Corp. This shift in monetary policy is especially relevant for VF Corp because easier credit conditions can encourage discretionary spending on branded clothing, footwear, and outdoor gear. Next, we’ll explore how the Fed’s signal of more supportive monetary policy could...

Recent performance puts 1st Source (SRCE) on investor radar 1st Source (SRCE) has quietly outperformed many regional peers, with the stock up about 7% over the past month and 14% year to date, prompting fresh interest in its valuation. See our latest analysis for 1st Source. That steady climb, with a roughly mid teens year to date share price return and a much stronger multiyear total shareholder return, suggests momentum is building as investors reassess the bank’s growth and risk profile at...

PNC Financial Services Group (PNC) has quietly pushed higher recently, with the stock up about 13% over the past month. That move has investors asking whether the regional banking heavyweight still offers value. See our latest analysis for PNC Financial Services Group. Zooming out, PNC’s roughly 12.7% 1 month share price return builds on a solid year to date rise. A hefty 5 year total shareholder return near 74% suggests long term compounding is still very much intact. If PNC’s momentum has...

In December 2025, ResMed announced it had received U.S. FDA clearance for Smart Comfort, an AI-enabled feature that uses more than 100 million nights of de-identified sleep data to recommend personalized comfort settings for new AirSense 11 CPAP users via the myAir app, with a phased U.S. rollout planned from early 2026. This marks the first FDA-cleared AI device focused on individualizing CPAP comfort to support obstructive sleep apnea adherence, while leaving core prescription therapy...

Recently, Simply Good Foods reported past fiscal 2025 results showing 9% net sales growth and modest adjusted EBITDA growth, while completing the OWYN integration, strengthening its balance sheet, and continuing to invest in its brands under cost inflation. Management’s cautious fiscal 2026 outlook for flat to slightly negative net sales growth and lower gross margins contrasts with strong consumption trends for Quest and OWYN, highlighting a portfolio in transition away from pressure points...

If you are wondering whether Realty Income is still attractively priced at around $57.72, or if the easy money has already been made, this article will walk through how the current price stacks up against its fundamentals. The stock has dipped about 1.3% over the last week but is still up 1.4% over 30 days, 9.7% year to date, and 10.4% over the past year. This quietly hints that the market may be rethinking both its growth prospects and risk profile. Recently, investors have been focused on...

Vistra (VST) is back in the spotlight after a flurry of bullish catalysts, from an S&P Global credit upgrade to new natural gas projects aimed at feeding power hungry data centers and AI growth. See our latest analysis for Vistra. Those catalysts are landing against a choppy backdrop, with the share price at $170.1 after a recent pullback that left the 90 day share price return at negative 18.88 percent. However, the year to date share price return of 13.66 percent and especially the five...

Earlier this week, Exxon Mobil announced that Chief Financial Officer and Senior Vice President Kathryn A. Mikells will retire on February 1, 2026, for health reasons, with long-time insider Neil A. Hansen set to assume both roles on that date. Alongside this leadership change, Exxon Mobil lifted its 2030 earnings and cash flow outlook on the back of technology-driven efficiency gains, higher expected output from advantaged assets like the Permian Basin, and ongoing cost reductions. We’ll...

Recently, BPI Direct BanKo and LLP Exotic Auto Finance each announced new partnerships with ACI Worldwide to overhaul their payment infrastructures, adopting ACI’s issuing, acquiring and Speedpay platforms to support real-time, omnichannel and digital wallet–enabled transactions. These wins highlight how ACI’s modular, cloud-ready payment solutions are being used across very different customer segments, from microfinance in the Philippines to US luxury auto finance, to cut costs, ease...

If you are wondering whether Semtech at around $72.89 is still worth a closer look, or if the big money has already been made, you are in the right place to work out what the current price really implies. The stock has pulled back about 8.4% over the last week, but it is still up 7.8% over 30 days and 17.4% year to date, with a 163.1% gain over 3 years that naturally raises questions about what comes next. Recent moves have been driven by growing investor attention on Semtech's role in...

Earlier this week, Guardant Health and Trial Library announced a collaboration to pair Guardant’s precision oncology diagnostics and real-world genomic data with Trial Library’s AI-powered matching and navigation platform, aiming to improve identification, referral and enrollment of cancer patients into clinical trials across more than 320 clinics and 1,500 providers in the United States. This partnership is distinctive because it connects Guardant’s data from over 1 million tested patients...

Recently released analysis highlighted that Constellation Brands’ rankings for financial strength, growth, valuation and predictability have weakened, with elevated debt levels and uncertain growth now weighing on perceptions of the business. An interesting implication is that the company’s historically important reputation for consistency is under renewed scrutiny, as lower predictability scores raise fresh questions about the reliability of its future revenue and earnings trends. Next,...

Wondering if Affirm Holdings is still worth your attention after its massive run a few years back, or if the story has quietly changed while no one was looking? After a huge 3 year gain of 564.5%, the stock has cooled off recently, slipping 1.1% over the last week, 14.8% over the last month, and sitting at a modest 7.6% gain year to date with a 4.9% loss over the past year. Recent moves have come as investors reassess buy now, pay later players like Affirm in light of shifting consumer...

If you are wondering whether Tilray Brands is finally a smart buy or just another volatile cannabis story, you are not alone. That is exactly what we are going to unpack here. The stock has surged about 65.3% over the past week, even though it is still down year to date and has had a rough 3 year stretch. This shows that sentiment can flip quickly when this name gets attention. Recently, Tilray has been in the spotlight as investors react to shifting expectations around US cannabis policy...

In late September 2025, MoonLake Immunotherapeutics revealed that its only drug candidate, sonelokimab, delivered disappointing Phase 3 results, leading to multiple securities class action lawsuits alleging the company misled investors about the drug’s efficacy and Nanobody advantages. The litigation centers on claims that MoonLake overstated sonelokimab’s superiority versus an existing treatment while allegedly not fully disclosing their similar biological targets and unproven clinical...

Celcuity (CELC) recently presented new Phase 3 VIKTORIA-1 data for gedatolisib to oncologists at the San Antonio Breast Cancer Symposium, showing clearly longer progression free survival versus fulvestrant in advanced HR positive, HER2 negative disease. See our latest analysis for Celcuity. These latest VIKTORIA-1 results land after a remarkable run for Celcuity, with a 30 day share price return of 23.61 percent and a 1 year total shareholder return of 740.65 percent, which some investors may...

The Brink's Company recently announced that its board approved a new share repurchase program authorizing up to US$750 million in buybacks, with the plan set to run through December 31, 2027. This authorization amounts to more than 15% of Brink's current market value, signaling management’s confidence in its cash generation and AMS/DRS-led growth strategy. Next, we’ll examine how Brink’s sizable new buyback authorization could reshape the existing investment narrative around capital...

Regencell Bioscience Holdings (NasdaqCM:RGC) has been under pressure after disclosing a Department of Justice subpoena into trading activity and its operational, financial, and accounting practices, a development that immediately sharpened investors focus on legal and governance risks. See our latest analysis for Regencell Bioscience Holdings. Even with the DOJ overhang, Regencell’s share price return has been explosive this year. A year to date surge and a strong 30 day share price gain...

Entegris (ENTG) is back in focus after recent investor commentary highlighted a puzzling mix of earnings beats, weaker guidance, and ongoing margin pressure tied to its expansion push in a still soft semiconductor demand environment. See our latest analysis for Entegris. The mixed reaction to Entegris’ latest quarter mirrors its share price story, with a recent 1 month share price return of 10.13 percent, a softer year to date share price return of 4.81 percent, and a 1 year total shareholder...

Recent Performance Sets the Stage Avista (AVA) has slipped about 7% over the past month but is still up around 6% year to date. This combination naturally raises the question of whether the pullback is offering a reasonable entry point. See our latest analysis for Avista. At a share price of $38.56, Avista’s recent 30 day share price return of negative 7.4 percent sits against a more constructive year to date gain and double digit one year total shareholder return. This suggests momentum has...

United Community Banks (UCB) just doubled down on shareholder returns, with its board signing off on a fresh $100 million stock repurchase program running from January 2026 through the end of that year. See our latest analysis for United Community Banks. That new buyback plan lands after a steady climb in sentiment, with a 7.5% 1 month share price return and a 5 year total shareholder return of 33.32%, suggesting momentum is gradually rebuilding from a muted recent patch. If this kind of...

In December 2025, Vestis Corporation reported fourth-quarter sales of US$712.01 million and a quarterly net loss of US$12.55 million, alongside a full-year net loss of US$40.22 million on sales of US$2,734.84 million, reversing the prior year’s profitability. Alongside these widened losses, Vestis guided for fiscal 2026 revenue to be flat to down 2% versus normalized 2025 levels, underscoring management’s cautious outlook on demand and execution. We’ll now examine how Vestis’s wider losses...